Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 30/3/2017
SIETES contiene 91734 citas

 
 
 1 a 20 de 48 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Gargiulo G, Windecker S, da Costa BR, Feres F, Hong M-K, Gilard M, Kim H-S, Colombo A, Bhatt DL, Kim B-K, Morice M-C, Park KW, Chieffo A, Palmerini T, Stone GW, Valgimigli M. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ 2016;355:i5483. [Ref.ID 100878]
2.Tiene citas relacionadas Cita con resumen
Weisz G, Généreux P, Iniguez A, Zurakowski A, Shechter M, Alexander KP, Dressler O, Osmukhina A, James S, Ohman EM, Ben-Yehuda O, Farzaneh-Far R, Stone GW, for the RIVER-PCI Investigators. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2016;387:136-45. [Ref.ID 100087]
3. Cita con resumen
Ellis SG, Kereiakes DJ, Metger C, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang ZS, Simonton C, Stone GW, for the ABSORB III Investigators. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med 2015;373:1905-15. [Ref.ID 99671]
4. Cita con resumen
Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, Vlachonjannis GJ, Jensen LO, Christiansen EH, Berencsi K, Valgimigli M, Orlandi C, Petrou M, Rapezzi C, Stone GW. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 2015;65:2496-507. [Ref.ID 99444]
5.Tiene citas relacionadas Cita con resumen
Palmerini T, Benedetto U, Bacchi-Reggiani L, Della Riva D, Biondi-Zoccai G, Feres F, Abizaid A, Hong M-K, Kim B-K, Jang Y, Kim H-S, Park KW, Genereux P, Bhatt DL, Orlandi C, De Servi S, Petrou M, Rapezzi C, Stone GW. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 2015;385:2371-82. [Ref.ID 99292]
6.Tiene citas relacionadas Cita con resumen
Han Y, Guo J, Zheng Y, Zang H, Wang Y, Chen S, Jiang T, Yang P, Chen J, Jiang D, Jing Q, Liang Z, Liu H, Zhao X, Li Y, Xu B, Stone GW, for the BRIGHT Investigators. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA 2015;313:1336-46. [Ref.ID 99015]
7.Tiene citas relacionadas Cita con resumen
Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L, French WJ, White HD, Harrington RA, for the CHAMPION Investigators. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013;382:1981-92. [Ref.ID 96671]
8.Tiene citas relacionadas
Windecker S, Bax JJ, Mayt A, Stone GW, Marber MS. Future treatment strategies in ST-segment elevation myocardial infarction. Lancet 2013;382:644-57. [Ref.ID 96028]
9.Tiene citas relacionadas Cita con resumen
Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg G, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimsky P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA, for the CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013;368:1303-13. [Ref.ID 95246]
10. Cita con resumen
Stone GW, Maehara A, Witzenbichler B, Godiewski J, Parise H, Dambrink J-HE, Ochala A, Carlton TW, Cristea E, Wolff SD, Dambrink J-HE, Brener SJ, Chowdhary S, El-Omar M, Neunteufl T, Metzger C, Karwoski T, Dizon JM, Mehran R, Gibson CM. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 2012;307:1817-26. [Ref.ID 92855]
11.Tiene citas relacionadas Cita con resumen
De Luca G, Dirksen MT, Spaulding C, Kelbaek H, Schalij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Díaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Cortese G, Suryapranata H, Stone GW, for the Drug-Eluting Stent in Primary Angioplasty (DESERT) Cooperation. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med 2012;172:611-21. [Ref.ID 92786]
12.Tiene citas relacionadas Cita con resumen
Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabaté M, Kim H-S, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393-402. [Ref.ID 92725]
13.Tiene citas relacionadas
Stone GW, Mehran R. Bivalirudin for patients with ST-elevation myocardial infarction. Authors' reply. Lancet 2011;378:1915-6. [Ref.ID 91912]
14.Tiene citas relacionadas
Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M, Parise H, Mehran R, on behalf of the HORIZONS-AMI Trial Investigators. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011;377:2193-204. [Ref.ID 91347]
15.
Stone GW. Acute coronary syndromes: finding meaning in OASIS 7. Lancet 2010;376:1203-5. [Ref.ID 89551]
16.Tiene citas relacionadas Cita con resumen
Stone GW, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ, for the SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362:1663-74. [Ref.ID 88459]
17.Tiene citas relacionadas Cita con resumen
Stone GW. Ticagrelor in ACS: redefining a new standard of care?. Lancet 2010;375:263-5. [Ref.ID 87548]
18.Tiene citas relacionadas Cita con resumen
Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack Jr CV, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, for the CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009;361:2330-41. [Ref.ID 87367]
19.Tiene citas relacionadas Cita con resumen
Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack Jr CV, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Bhatt DL. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009;361:2318-29. [Ref.ID 87366]
20.Tiene citas relacionadas Cita con resumen
Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikoslky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW, for the HORIZONS-AMI Trial Investigators. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009;374:1149-59. [Ref.ID 86874]
Seleccionar todas
 
 1 a 20 de 48 siguiente >>